A rapid stability-indicating, fused-core HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial fixed dose combination products

BACKGROUND: Artemisinin-based fixed dose combination (FDC) products are recommended by World Health Organization (WHO) as a first-line treatment. However, the current artemisinin FDC products, such as β-artemether and lumefantrine, are inherently unstable and require controlled distribution and stor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Suleman, Sultan, Vandercruyssen, Kirsten, Wynendaele, Evelien, D’Hondt, Matthias, Bracke, Nathalie, Duchateau, Luc, Burvenich, Christian, Peremans, Kathelijne, De Spiegeleer, Bart
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3651282/
https://ncbi.nlm.nih.gov/pubmed/23631682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-12-145
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars